Relapsing Forms Of Multiple Sclerosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for relapsing forms of multiple sclerosis. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
3
Active US patents
30/100
Avg vulnerability
$500M
Annual revenue covered

Originators in Relapsing Forms Of Multiple Sclerosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Biogen 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating relapsing forms of multiple sclerosis. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vumerity
DIROXIMEL FUMARATE
 Biogen 3 30 $500M 2033-09-20

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10080733 Vumerity method of use 45 2033-09-20
9090558 Vumerity method of use 45 2033-09-20
8669281 Vumerity composition of matter 0 2033-10-29

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8669281 Vumerity composition of matter 0 2033-10-29
10080733 Vumerity method of use 45 2033-09-20
9090558 Vumerity method of use 45 2033-09-20

Related